Cancer cachexia, characterized by anorexia and loss of muscle mass, has a negative effect on patient quality of life. In addition, the medical management of cancer cachexia remains difficult because of the multifactorial pathophysiology involved. Various drugs and other treatments have been tested with limited success, but a recent clinical trial suggests that multitargeted treatments would be effective. In this article, we describe such a combination therapy for cancer cachexia.